Controversies in Surgical Management of the Node-Positive Neck After Chemoradiation

被引:31
作者
Lango, Miriam N. [2 ]
Myers, Jeffrey N. [1 ]
Garden, Adam S. [3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[2] Fox Chase Canc Ctr, Dept Surg Oncol, Head & Neck Sect, Philadelphia, PA 19111 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
SQUAMOUS-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; DEFINITIVE RADIATION-THERAPY; ORGAN-PRESERVATION THERAPY; PHASE-II TRIAL; ADVANCED HEAD; CONCURRENT CHEMORADIOTHERAPY; POSTRADIOTHERAPY NECK; OROPHARYNGEAL CANCER; COMPUTED-TOMOGRAPHY;
D O I
10.1016/j.semradonc.2008.09.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The addition of chemotherapy to radiation in the treatment of advanced-staged head and neck cancer has improved local-regional control and increased complete clinical and pathologic response rates in the neck. However, for those patients with residual neck disease on a posttreatment computed tomography (CT) scan, there remains significant controversy as to how to further assess the neck for the presence of a viable tumor and when to perform a neck dissection. Recently, investigators from Australia have assembled level I evidence to support the use of positron-emission tomography (PET) scanning to assess treatment response and have shown a very high negative predictive value for patients with a negative PET at 12 weeks after the completion of therapy. These data support the practice of observing PET-negative necks and intervening with neck dissection in PET-positive necks. However, not all investigators, practitioners, and patients are comfortable with delaying intervention for such a long time interval after treatment. The authors favor assessment of the neck with a CT scan at 6 weeks after the completion of chemoradiotherapy and recommend neck dissection for patients with radiographic residual disease at this time point. One rationale is that 6 weeks is an optimal window for operative intervention after acute treatment effects have subsided and before extensive fibrosis and scarring, which translates to less morbidity for the patient who is treated surgically. Another rationale is that those who develop regional recurrence can be hard to salvage surgically, and waiting an additional 6 weeks could allow for the expansion of resistant clones. The significance of this is unclear, however, because patients with residual disease are at a higher risk for local and distant as well as regional failure. Thus, further prospective studies of the role of postchemoradiotherapy PET scanning and neck dissection are needed.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 43 条
[1]   Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution [J].
Adelstein, DJ ;
Saxton, JP ;
Rybicki, LA ;
Esclamado, RM ;
Wood, BG ;
Strome, M ;
Lavertu, P ;
Lorenz, RR ;
Carroll, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1064-1071
[2]   Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14 [J].
Ang, KK ;
Harris, J ;
Garden, AS ;
Trotti, A ;
Jones, CU ;
Carrascosa, L ;
Cheng, JD ;
Spencer, SS ;
Forastiere, A ;
Weber, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :3008-3015
[3]   Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer [J].
Argiris, A ;
Stenson, KM ;
Brockstein, BE ;
Mittal, BB ;
Pelzer, H ;
Kies, MS ;
Jayaram, P ;
Portugal, L ;
Wenig, BL ;
Rosen, FR ;
Haraf, DJ ;
Vokes, EE .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2004, 26 (05) :447-455
[4]   REGIONAL OUTCOME IN OROPHARYNGEAL AND PHARYNGOLARYNGEAL CANCER TREATED WITH HIGH-DOSE PER FRACTION RADIOTHERAPY - ANALYSIS OF NECK DISEASE RESPONSE IN 1646 CASES [J].
BERNIER, J ;
BATAINI, JP .
RADIOTHERAPY AND ONCOLOGY, 1986, 6 (02) :87-103
[5]  
Boyd TS, 1998, HEAD NECK-J SCI SPEC, V20, P132, DOI 10.1002/(SICI)1097-0347(199803)20:2<132::AID-HED6>3.0.CO
[6]  
2-3
[7]   Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: Consensus, controversy, and conundrum [J].
Brizel, DM ;
Esclamado, R .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (17) :2612-2617
[8]   The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease [J].
Clayman, GL ;
Johnson, CJ ;
Morrison, W ;
Ginsberg, L ;
Lippman, SM .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2001, 127 (02) :135-139
[9]  
CONLEY J, 1975, LARYNGOSCOPE, V85, P1344, DOI 10.1288/00005537-197508000-00010
[10]   N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders - Results of Trans Tasman Radiation Oncology Group study 98.02 [J].
Corry, June ;
Peters, Lester ;
Fisher, Richard ;
Macann, Andrew ;
Jackson, Michael ;
McClure, Bev ;
Rischin, Danny .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (06) :737-742